Vitamin D Levels Tied to COVID-19 Risk for African-Americans
|
By LabMedica International staff writers Posted on 29 Mar 2021 |

Image: A blood test for Vitamin D showed that African-Americans individuals with low Vitamin D were more at risk from COVID-19 (Photo courtesy of Getty Images)
Vitamin D has diverse physiological effects, including on calcium regulation, bone density, and immune function. Deficient levels, typically defined as 25-hydroxyvitamin D (also known as calcifediol) level less than 20 ng/mL are common, especially in African-Americans individuals.
Vitamin D is also important for immune function, and a meta-analysis of randomized clinical trials using daily or weekly dosing has found vitamin D supplementation was associated with substantially decreased viral respiratory infections, especially in individuals who were deficient in vitamin D, but also individuals without a deficient level.
A team of Medical Scientists from The University of Chicago (Chicago, IL, USA) examined whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for African-Americans individuals. The team assessed data from 4,638 people tested for COVID-19 from March 3, 2020 to April 10, 2020, who also had data on vitamin D levels within a year prior to COVID-19 testing. COVID-19 status was determined by the Centers for Disease Control and Prevention or Viacor polymerase chain reaction (PCR, Lee's Summit, MO, USA) test used until in-house testing with the Cobas SARS-CoV-2 RT-PCR (Roche Diagnostics, Rotkreuz, Switzerland) began March 15, 2020.
The primary outcome was whether vitamin D level within 14 days was associated with testing positive for COVID-19, and the group controlled for time and vitamin D treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators. The team reported that patients' mean age was around 53 and 69% were women; 49% were African-Americans and 43% were White. They were stratified into four groups by vitamin D levels. African-Americans individuals were more likely than White individuals to have vitamin D levels below 20 ng/mL (36% and 16%, respectively), and more likely to test positive for COVID-19 (9% and 5%, respectively). COVID-19 risk decreased by 5% for each 1 ng/mL increment among individuals with a level of 30 ng/mL or greater in African-Americans individuals.
The authors concluded that COVID-19 risk increased among African-Americans individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. The study was published on March 19, 2021 in the journal JAMA Network Open.
Related Links:
The University of Chicago
Viacor
Roche Diagnostics
Vitamin D is also important for immune function, and a meta-analysis of randomized clinical trials using daily or weekly dosing has found vitamin D supplementation was associated with substantially decreased viral respiratory infections, especially in individuals who were deficient in vitamin D, but also individuals without a deficient level.
A team of Medical Scientists from The University of Chicago (Chicago, IL, USA) examined whether COVID-19 test results are associated with differences in vitamin D levels of 30 ng/mL or greater, including for White individuals and for African-Americans individuals. The team assessed data from 4,638 people tested for COVID-19 from March 3, 2020 to April 10, 2020, who also had data on vitamin D levels within a year prior to COVID-19 testing. COVID-19 status was determined by the Centers for Disease Control and Prevention or Viacor polymerase chain reaction (PCR, Lee's Summit, MO, USA) test used until in-house testing with the Cobas SARS-CoV-2 RT-PCR (Roche Diagnostics, Rotkreuz, Switzerland) began March 15, 2020.
The primary outcome was whether vitamin D level within 14 days was associated with testing positive for COVID-19, and the group controlled for time and vitamin D treatment changes since the vitamin D level was measured, as well as demographic characteristics and comorbidity indicators. The team reported that patients' mean age was around 53 and 69% were women; 49% were African-Americans and 43% were White. They were stratified into four groups by vitamin D levels. African-Americans individuals were more likely than White individuals to have vitamin D levels below 20 ng/mL (36% and 16%, respectively), and more likely to test positive for COVID-19 (9% and 5%, respectively). COVID-19 risk decreased by 5% for each 1 ng/mL increment among individuals with a level of 30 ng/mL or greater in African-Americans individuals.
The authors concluded that COVID-19 risk increased among African-Americans individuals with vitamin D level less than 40 ng/mL compared with those with 40 ng/mL or greater and decreased with increasing levels among individuals with levels greater than 30 ng/mL. No significant associations were noted for White individuals. The study was published on March 19, 2021 in the journal JAMA Network Open.
Related Links:
The University of Chicago
Viacor
Roche Diagnostics
Latest Clinical Chem. News
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
Channels
Molecular Diagnostics
view channel
Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
Human papillomavirus (HPV)-associated head and neck cancers are frequently treated with surgery, but some patients experience recurrence due to residual microscopic disease. Postoperative decisions about... Read more
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








